- Corporate Officers - W
- Whitfield Roy A
Insider Trading History of Whitfield Roy A
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Whitfield Roy A since 2008.
This trader's CIK number is 936728.
At the time of last reporting, Whitfield Roy A was the Director of Nektar Therapeutics. (stock ticker symbol NKTR).
Also see all insider trading activities at Nektar Therapeutics.
Note that in the past
WHITFIELD ROY A also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Incyte Corp (INCY) by Whitfield Roy A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2013 | INCY | 0 | $0 | 190,000 | $5,757,698 | 45,000 | $329,400 |
| 2012 | INCY | 0 | $0 | 40,000 | $796,000 | 50,000 | $177,980 |
| 2011 | INCY | 0 | $0 | 80,000 | $1,460,499 | 0 | $0 |
| 2010 | INCY | 0 | $0 | 65,253 | $1,098,858 | 0 | $0 |
Yearly summary of insider trading at Illumina, Inc. (ILMN) by Whitfield Roy A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2016 | ILMN | 0 | $0 | 11,800 | $1,882,552 | 10,000 | $428,200 |
| 2015 | ILMN | 0 | $0 | 35,450 | $6,980,676 | 35,450 | $1,177,911 |
| 2014 | ILMN | 0 | $0 | 14,000 | $2,315,520 | 14,000 | $274,540 |
| 2013 | ILMN | 0 | $0 | 4,000 | $356,980 | 4,000 | $78,440 |
| 2011 | ILMN | 0 | $0 | 2,000 | $144,300 | 800 | $15,688 |
| 2010 | ILMN | 0 | $0 | 6,000 | $220,320 | 6,000 | $117,660 |
| 2009 | ILMN | 0 | $0 | 20,456 | $746,930 | 20,456 | $321,272 |
Yearly summary of insider trading at Nektar Therapeutics (NKTR) by Whitfield Roy A
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | NKTR | 0 | $0 | 30,000 | $17,100 | 0 | $0 |
| 2021 | NKTR | 0 | $0 | 0 | $0 | 40,000 | $552,000 |
| 2020 | NKTR | 0 | $0 | 0 | $0 | 30,000 | $277,200 |
| 2019 | NKTR | 0 | $0 | 0 | $0 | 10,000 | $92,400 |
| 2018 | NKTR | 5,000 | $290,431 | 0 | $0 | 30,000 | $427,800 |
| 2017 | NKTR | 35,000 | $628,250 | 0 | $0 | 14,000 | $117,179 |
| 2016 | NKTR | 0 | $0 | 0 | $0 | 61,000 | $286,120 |
| 2015 | NKTR | 0 | $0 | 0 | $0 | 15,000 | $132,150 |
| 2013 | NKTR | 0 | $0 | 12,500 | $155,125 | 12,500 | $142,625 |
| 2011 | NKTR | 0 | $0 | 0 | $0 | 10,000 | $0 |
| 2008 | NKTR | 0 | $0 | 0 | $0 | 5,000 | $0 |
Insider trading activities at 3 companies by Whitfield Roy A:
1. Incyte Corp (INCY)
2. Illumina, Inc. (ILMN)
3. Nektar Therapeutics (NKTR)
Table 1. Insider trading of Incyte Corp (INCY) by Whitfield Roy A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2013-12-17 | INCY | Option Ex | 45,000 | 7.32 | 329,400 |
| 2013-11-18 | INCY | Sale | 50,000 | 47.37 | 2,368,500 |
| 2013-08-19 | INCY | Sale | 50,000 | 26.70 | 1,335,000 |
| 2013-05-17 | INCY | Sale | 40,000 | 23.08 | 923,199 |
| 2013-03-14 | INCY | Sale | 10,000 | 25.08 | 250,799 |
| 2013-03-01 | INCY | Sale | 10,000 | 22.56 | 225,600 |
| 2013-02-19 | INCY | Sale | 30,000 | 21.82 | 654,600 |
| 2012-05-24 | INCY | Sale | 20,000 | 22.27 | 445,400 |
| 2012-03-21 | INCY | Option Ex | 14,000 | 4.15 | 58,100 |
| 2012-03-19 | INCY | Option Ex | 36,000 | 3.33 | 119,880 |
| 2012-02-17 | INCY | Sale | 20,000 | 17.53 | 350,600 |
| 2011-06-16 | INCY | Sale | 4,502 | 18.02 | 81,126 |
| 2011-06-17 | INCY | Sale | 15,498 | 18.04 | 279,583 |
| 2011-05-11 | INCY | Sale | 10,000 | 20.02 | 200,200 |
| 2011-05-12 | INCY | Sale | 10,000 | 20.21 | 202,140 |
| 2011-05-09 | INCY | Sale | 10,000 | 19.78 | 197,800 |
| 2011-05-05 | INCY | Sale | 10,000 | 19.24 | 192,440 |
| 2011-04-05 | INCY | Sale | 10,000 | 16.03 | 160,260 |
| 2011-03-25 | INCY | Sale | 10,000 | 14.70 | 146,950 |
| 2010-12-22 | INCY | Sale | 10,000 | 17.00 | 170,000 |
| 2010-12-23 | INCY | Sale | 10,000 | 17.11 | 171,090 |
| 2010-11-17 | INCY | Sale | 1,000 | 15.90 | 15,900 |
| 2010-11-16 | INCY | Sale | 10,000 | 16.01 | 160,100 |
| 2010-10-25 | INCY | Sale | 29,523 | 16.99 | 501,595 |
| 2010-10-22 | INCY | Sale | 4,730 | 16.95 | 80,173 |
Table 2. Insider trading of Illumina, Inc. (ILMN) by Whitfield Roy A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2016-08-12 | ILMN | Option Ex | 4,000 | 42.82 | 171,280 |
| 2016-08-12 | ILMN | Sale | 4,000 | 167.22 | 668,880 |
| 2016-06-13 | ILMN | Option Ex | 2,000 | 42.82 | 85,640 |
| 2016-06-13 | ILMN | Sale | 3,800 | 140.44 | 533,672 |
| 2016-04-12 | ILMN | Sale | 4,000 | 170.00 | 680,000 |
| 2016-04-12 | ILMN | Option Ex | 4,000 | 42.82 | 171,280 |
| 2015-12-14 | ILMN | Sale | 3,750 | 175.07 | 656,512 |
| 2015-12-14 | ILMN | Option Ex | 3,750 | 36.29 | 136,087 |
| 2015-09-04 | ILMN | Option Ex | 4,500 | 36.29 | 163,305 |
| 2015-08-05 | ILMN | Sale | 4,500 | 215.22 | 968,490 |
| 2015-08-05 | ILMN | Option Ex | 4,500 | 37.72 | 169,717 |
| 2015-09-04 | ILMN | Sale | 4,500 | 192.63 | 866,835 |
| 2015-07-06 | ILMN | Option Ex | 4,500 | 39.14 | 176,130 |
| 2015-07-06 | ILMN | Sale | 4,500 | 218.21 | 981,922 |
| 2015-06-05 | ILMN | Sale | 4,500 | 207.49 | 933,705 |
| 2015-06-05 | ILMN | Option Ex | 4,500 | 39.14 | 176,130 |
| 2015-05-05 | ILMN | Sale | 4,500 | 188.42 | 847,890 |
| 2015-05-05 | ILMN | Option Ex | 4,500 | 39.14 | 176,130 |
| 2015-04-06 | ILMN | Option Ex | 4,600 | 19.61 | 90,206 |
| 2015-04-06 | ILMN | Sale | 4,600 | 181.32 | 834,072 |
| 2015-03-05 | ILMN | Sale | 4,600 | 193.75 | 891,250 |
| 2015-03-05 | ILMN | Option Ex | 4,600 | 19.61 | 90,206 |
| 2014-11-17 | ILMN | Option Ex | 4,000 | 19.61 | 78,440 |
| 2014-11-17 | ILMN | Sale | 4,000 | 178.26 | 713,040 |
| 2014-08-15 | ILMN | Option Ex | 4,000 | 19.61 | 78,440 |
| 2014-08-15 | ILMN | Sale | 4,000 | 169.28 | 677,120 |
| 2014-05-15 | ILMN | Option Ex | 4,000 | 19.61 | 78,440 |
| 2014-05-15 | ILMN | Sale | 4,000 | 143.71 | 574,840 |
| 2014-02-24 | ILMN | Sale | 2,000 | 175.26 | 350,520 |
| 2014-02-24 | ILMN | Option Ex | 2,000 | 19.61 | 39,220 |
| 2013-11-25 | ILMN | Option Ex | 2,000 | 19.61 | 39,220 |
| 2013-11-25 | ILMN | Sale | 2,000 | 100.00 | 200,000 |
| 2013-09-03 | ILMN | Option Ex | 2,000 | 19.61 | 39,220 |
| 2013-09-03 | ILMN | Sale | 2,000 | 78.49 | 156,980 |
| 2011-06-02 | ILMN | Option Ex | 800 | 19.61 | 15,688 |
| 2011-06-02 | ILMN | Sale | 2,000 | 72.15 | 144,300 |
| 2010-04-26 | ILMN | Option Ex | 3,000 | 19.61 | 58,830 |
| 2010-04-26 | ILMN | Sale | 3,000 | 36.89 | 110,676 |
| 2010-01-25 | ILMN | Option Ex | 3,000 | 19.61 | 58,830 |
| 2010-01-25 | ILMN | Sale | 3,000 | 36.55 | 109,644 |
| 2009-10-26 | ILMN | Option Ex | 3,000 | 19.61 | 58,830 |
| 2009-10-26 | ILMN | Sale | 3,000 | 41.45 | 124,335 |
| 2009-08-10 | ILMN | Option Ex | 3,000 | 19.61 | 58,830 |
| 2009-08-10 | ILMN | Sale | 3,000 | 36.15 | 108,453 |
| 2009-05-28 | ILMN | Option Ex | 14,456 | 14.09 | 203,612 |
| 2009-05-28 | ILMN | Sale | 14,456 | 35.57 | 514,142 |
Table 3. Insider trading of Nektar Therapeutics (NKTR) by Whitfield Roy A
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-06-14 | NKTR | Sale | 30,000 | .57 | 17,100 |
| 2021-09-16 | NKTR | Option Ex | 40,000 | 13.80 | 552,000 |
| 2020-09-04 | NKTR | Option Ex | 30,000 | 9.24 | 277,200 |
| 2019-12-18 | NKTR | Option Ex | 10,000 | 9.24 | 92,400 |
| 2018-06-06 | NKTR | Buy | 3,400 | 59.44 | 202,079 |
| 2018-06-05 | NKTR | Buy | 1,600 | 55.22 | 88,352 |
| 2018-04-17 | NKTR | Option Ex | 30,000 | 14.26 | 427,800 |
| 2017-08-10 | NKTR | Buy | 35,000 | 17.95 | 628,250 |
| 2017-03-15 | NKTR | Option Ex | 14,000 | 8.37 | 117,179 |
| 2016-09-23 | NKTR | Option Ex | 46,000 | 6.22 | 286,120 |
| 2016-09-15 | NKTR | Option Ex | 15,000 | .00 | 0 |
| 2015-09-11 | NKTR | Option Ex | 15,000 | 8.81 | 132,150 |
| 2013-08-05 | NKTR | Sale | 12,500 | 12.41 | 155,125 |
| 2013-08-05 | NKTR | Option Ex | 12,500 | 11.41 | 142,625 |
| 2011-03-07 | NKTR | Option Ex | 10,000 | .00 | 0 |
| 2008-11-14 | NKTR | Option Ex | 5,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Whitfield Roy A
(Director of Nektar Therapeutics at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.